What top creators are saying about Hims & Hers Health, Inc.(HIMS)— Page 3

Momentum trade driven by internet narratives and political mentions.

High-conviction short squeeze candidate following loosening of peptide restrictions.

The speaker remains invested despite high volatility, viewing peptides as a potential catalyst for long-term tech disruption.

Positioned as a primary play for the 'looksmaxxing' trend, though historically volatile and momentum-driven.

Regulatory de-risking of peptides and high short interest create a major revenue catalyst and short squeeze potential.

Positioned to lead the legitimate peptide market through regulatory clarity, in-house manufacturing, and a move toward partnerships with big pharma.

Surged on news of FDA moving toward regulatory clarity for peptide therapy.

Utilizes 'MedMatch' AI for personalized prescriptions and is undervalued as an underlying AI-driven platform rather than just a GLP-1 play.

High volatility and concerns regarding product side effects.

Up 8% but noted for high volatility and concerns regarding product side effects.

Considered 'dirt cheap' with a strong Rule of 40 score of 48 and defensive growth qualities decoupled from macro tensions.

Part of the expanded IA13 basket of high-growth AI-related companies.

Stock is down and speaker questions the long-term impact of product side effects.

Significant disconnect between fundamental performance and share price; 100,000 monthly weight loss subscriptions could add $210M in ARR not yet priced in.

The CFO's plan to sell 75% of his personal shareholdings and concerns over product concentration in hair loss treatments suggest a lack of executive confidence and high risk.

Shifting to a comprehensive healthcare disruptor using a 'loss-leader' strategy with lab screenings and proprietary EHR to capture long-term customers in weight loss and longevity.

Transitioning from a D2C provider to a healthcare disruptor by verticalizing infrastructure, including pharmacy fulfillment and diagnostics, while scaling GLP-1 accessibility.

Current price is a disconnect from strong fundamentals; company has a 95% recurring revenue model and is expanding into peptide manufacturing.

May benefit from compounded GLP-1 versions, but analysts are skeptical of long-term moat.

Significant price drop is viewed as nonsensical relative to strong company performance; seen as an opportunity.

Noted for its pivot into the GLP-1 weight loss space and ownership of its entire supply chain.

The speaker views the recent pullback to $19 as a major buying opportunity, citing strong recurring revenue, expansion into GLP-1s and peptides, and a valuation of 2x forward gross profit.

Experienced a massive 10% drop, described as 'carnage'.

Significant disconnect between perfect business execution and a 70% stock decline; viewed as a contrarian opportunity due to fundamental undervaluation.

Current price drops are viewed as nonsensical and driven by market fear rather than fundamentals, representing a potential contrarian opportunity.

Major legal risks have been resolved and new branded GLP-1 product launches with Novo Nordisk provide a massive growth catalyst not yet reflected in guidance.

Positive momentum from expansion into peptides and weight-loss treatments leveraging its customer database.

Deeply undervalued at $21 as legal risks and regulatory overhangs from Novo Nordisk and the FDA have been resolved; positioned for growth through peptide partnerships.

Positioned as the 'McDonald's of Peptides' to bring anti-aging and GLP-1 treatments to the mass market.

Viewed as a high-conviction play with favorable risk-reward despite sector volatility.

Used as a comparison for stocks where price response does not match the quality of news.

Strategic pivot into the peptide and GLP-1 weight-loss space with a vertically integrated supply chain advantage.

Bear thesis dismantled after Novo Nordisk partnership and FDA support; stock is irrationally priced near bear-market lows despite reduced legal risk.

Showing strength with a 5% price increase amid broader market volatility.

Strong Rule of 40 score of 60 with underpriced growth; bear thesis on GLP-1 lawsuits was invalidated by Novo Nordisk partnership.

Viewed as a resilient subscription model for 'must-have' pills; current price drop is seen as an unfair result of basket selling rather than poor fundamentals.

Considered undervalued relative to growth despite a recent rally; legal overhang regarding GLP-1 drugs has largely dissipated.

Currently caught in a rally of high-risk 'animal spirit' assets.

Showing idiosyncratic strength, up double digits despite broader market weakness.

Upgraded by Bank of America following resolution of Novo Nordisk conflicts; high volatility and short squeeze potential.

Surged 40% after Novo Nordisk dropped its lawsuit; high short interest could lead to a squeeze to $30.

Showing idiosyncratic strength and high growth, up 42% regardless of the macro environment.

Significant de-risking following a partnership with Novo Nordisk for Wegovy; stock viewed as undervalued with potential for 35% to 45% annual growth.

Surged 50% after a lawsuit dismissal; potential for partnership in GLP-1 distribution and short squeeze potential.

Significant trend reversal and green momentum following a partnership announcement, decoupling from the broader market.

Strategic partnership with Novo Nordisk to sell branded GLP-1 products and potential for an epic short squeeze due to high short interest and improving fundamentals.

Used as a proxy for the high-growth sector; represents a recovery opportunity if interest rates return to zero.

Market is currently treating it as a pure GLP-1 play, ignoring other fundamentals; potential for 3x returns for those who can withstand 60% drawdowns.

Viewed as undervalued with strong revenue growth projected at 24-33% for 2026 including the Eucalyptus acquisition; strong competitive moat via physical medical networks.

Preferred as a more stable alternative in the Direct-to-Consumer space compared to Oddity Tech.